Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Brain Metastases
- Lung Cancer Non-small Cell Stage IV
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03769103
- Collaborators
- AstraZeneca
- Princess Margaret Hospital, Canada
- Sunnybrook Health Sciences Centre
- Investigators
- Principal Investigator: Shilo V Lefresne, MD, FRCPC BC Cancer, Vancouver Centre Principal Investigator: Cheryl Ho, MD, FRCPC BC Cancer, Vancouver Centre
Get Well Soon